
		• American College of Obstetricians and Gynecologists - 56th Annual Clinical Meeting May 3-7, 2008 • South Atlantic Association of Obstetricians and Gynecologists Calendar • European Board & College of Obstetrics and Gynaecology 2008 Congress • Society of Gynecologic Oncologists Annual Meeting on Women's Cancer March 9-12, 2008


		• Recommended immunization schedules for children and adolescents: United States, 2007. • Adult preventive health care: immunizations. • Cervical cancer screening guideline: October 2006. • Cervical cancer screening for women who attend STD clinics or have a history of STDs. Sexually transmitted diseases treatment guidelines 2006. • Human papillomavirus (HPV). • Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). • HPV infection and genital warts. Sexually transmitted diseases treatment guidelines 2006. • Clinical prevention guidance. Sexually transmitted diseases treatment guidelines 2006.


		• Benign Cervical Lesions • Cervical Cancer • Cervix, Cancer • Condyloma Acuminata • Human Papillomavirus • Papillomavirus • Urethral Warts • Warts, Genital • View All HPV and Cervical Cancer Articles


		• "Cauliflower" condyloma of the penis. • Stage Ib carcinoma confined to the cervix. • Condyloma acuminatum in a patient with a history of an allograft renal transplant. • Condyloma acuminata. • Anal condyloma acuminatum. • The extensive labial involvement. • These condylomata extend to the anal verge. • Small papilloma of the anus. • Small papilloma of the vulva. • View All HPV and Cervical Cancer Multimedia Files


		• All About HPV • Cervical Cancer • Cervical Cancer • Cervical Cancer (Cancer of the Cervix) • Cervical Cancer Health Center • Cervical Cancer Vaccine: 12 Questions & Answers • Genital Warts HPV Infection • Human Papillomaviruses (HPVs) and Genital Warts • Pap Smear • Pap Smear

HPV and Cervical Cancer Resource Center

Benign Cervical Lesions

Obstetrics/Gynecology

HPV can infect the ectocervix and can cause warty lesions similar to those seen in the vagina or on the vulva; however, the virus on the cervix typically causes flat warts. These are macular or papular lesions that become more visible to the naked eye when swabbed with 3-5% acetic acid.

Cervical Cancer

Obstetrics/Gynecology

Cervical cancer is the second most common malignancy in women worldwide, and it remains a leading cause of cancer-related death for women in developing countries. In the United States, cervical cancer is relatively uncommon. The incidence of invasive cervical cancer has declined steadily in the United States over the past few decades; however, it continues to rise in many developing countries. The change in the epidemiological trend in the United States has been attributed to mass screening with Papanicolaou tests (Pap smears).

Cervix, Cancer

Radiology

Cancer of the uterine cervix is largely a preventable disease characterized by a long lead-time, with precancerous lesions gradually progressing through recognizable stages before developing into invasive disease. The disease process is almost certainly curable if it is identified prior to its progression to invasive cancer.

Condyloma Acuminata

Obstetrics/Gynecology

The viral nature of genital warts was first recognized in 1907 when Ciuffo induced warts after autoinoculation of cell-free wart extracts (Ciuffo, 1907). With the development of molecular biology techniques, the human papillomavirus (HPV) was identified as the virus responsible for condyloma acuminatum.

Human Papillomavirus

Infectious Diseases

Human papillomaviruses (HPVs) produce epithelial tumors of the skin and mucous membranes. More than 100 HPV types have been detected, and the genomes of more than 80 have been completely sequenced. The current classification system, which is based on similarities in their genomic sequences, generally correlates with the 3 categories used to describe HPV clinically: anogenital and/or mucosal, nongenital cutaneous, and epidermodysplasia verruciformis (EV).

A Single Centre Study to Evaluate the Safety and Immunogenicity of the HPV Vaccine (GSK-580299) in Chinese Females

This study will evaluate the safety and immunogenicity (exploratory objective) of three doses of GSK Biologicals HPV vaccine (GSK-580299) administered intramuscularly over 6 months, in healthy, females, aged 18-35 years of Chinese origin, residing in China.

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

This study will further evaluate induction of immune memory and anamnestic responses in women who previously took part in the primary study (580299/001) and follow-up study (580299/007).

Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions

There are two main goals in this study. First, the investigators would like to establish and compare the differences of HPV type 16 E7-specific immunologic responses between the normal population, people with HPV infection, patients with cervical intraepithelial neoplastic (CIN) lesions, and patients with cervical cancer. Second, they would like to correlate the disease severity of cervical cancer with the immunologic responses to HPV type 16 E7 antigen.

Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.

The current study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 in female subjects aged 10-25 years enrolled in Africa.

Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 15 - 25 Years of Age

The current Phase IIIb study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an alternative dosing schedule as compared to the standard dosing schedule in young female subjects aged 15 - 25 years.

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 Administered in Healthy Adolescents

The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

To determine whether certain types of HPV are more risky than others and if so, whether they warrant separate detection in screening for cervical precancer and cancer. To determine if lasting infection by different HPV types carry different risk of cervical precancer and cancer. To determine what viral and genetic factors influence the development of cervical precancer and cancer. To evaluate new HPV tests and new biomarkers of cervical cancer risk

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bios' HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

In this partially-blind study, GSK Biologicals will evaluate the safety and immunogenicity of the HPV vaccine using an alternative schedule and an alternative dosing when administered in healthy young females aged 9 to 25 years, as compared to the standard HPV vaccine.

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24

Saslow D, Wheeler CM. Human papillomavirus vaccines: who will pay, who will receive, when to administer? Ethn. Dis 2007 Spring;17(2 Suppl 2):S2-8-13

Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE; Gynecologic Cancer Advisory Group, Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28.

Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol. 2007 Mar;38(3):189-97. Epub 2007 Jan 25.

Monk BJ, Mahdavi A. Human papillomavirus vaccine: a new chance to prevent cervical cancer. Recent Results Cancer Res. 2007;174:81-90.

Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaec Oncol. 2005;26(2):129-42.

Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007 Apr;7(4):289-96.

Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007 Jan;13(1):28-41.

FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27.

Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003 Aug 13;290(6):781-9.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007 May 19;369(9574):1693-702.

We subscribe to the
HONcode principles of the
Health On the Net Foundation

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.